Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Diseasemodifying drugs - Biotech, Pharma and Life Science Channel

13:37 EDT 31st July 2014 | BioPortfolio

PubMed Articles [4629 Associated PubMed Articles listed on BioPortfolio]

In brief: Khedzela - a new brand of desvenlafaxine.

New oral anticogulants for acute venous thromboembolism.

Simeprevir (Olysio) for chronic hepatitis c.

Qualitative screening of 116 veterinary drugs in feed by liquid chromatography-high resolution mass spectrometry: Potential application to quantitative analysis.

Veterinarian and human pharmaceuticals may be intentionally added to animal feed to enhance animal production. Monitoring these substances is necessary for protecting the consumers. In this work, a sc...

Effect of irradiated sodium alginate and phosphorus on biomass and artemisinin production in Artemisia annua.

It is now being realized that irradiation products of natural bioactive agents can also be beneficially utilized to impart value addition in agriculture by converting these bioactive agents into more...

Porous silicon-cyclodextrin based polymer composites for drug delivery applications.

One of the main applications of porous silicon (PSi) in biomedicine is drug release, either as a single material or as a part of a composite. PSi composites are attractive candidates for drug delivery...

Controlling the complexation of polysaccharides into multi-functional colloidal assemblies for nanomedicine.

The controlled assembly of oppositely charged polysaccharides led to colloids stable in physiological media, capable of encapsulating a molecular drug and of sorbing proteins at their interface. Two t...

Seasonal changes in antibiotics, antidepressants/psychiatric drugs, antihistamines and lipid regulators in a wastewater treatment plant.

Seasonal changes in the concentration of 21 pharmaceuticals in a wastewater treatment plant (WWTP) in České Budějovice were investigated over 12months. The target compounds were 10 antibiotics, 4 a...

Enantioselective biodegradation of fluoxetine by the bacterial strain Labrys portucalensis F11.

Fluoxetine (FLX) is a chiral fluorinated pharmaceutical indicated mainly for the treatment of depression and is one of the most dispensed drugs in the world. There is clear evidence of environmental c...

Concentration evolution of pharmaceutically active compounds in raw urban and industrial wastewater.

The distribution of pharmaceutically active compounds in the environment has been reported in several works in which wastewater treatment plants have been identified as the main source of these compou...

News Articles [5453 Associated News Articles listed on BioPortfolio]

US seniors save more than $11.5 billion on Rx drugs since 2010

Information released by the US Department of Health and Human Services shows that more than 8.2 million seniors and people with disabilities with Medicare continue to enjoy prescription drug savings a...

New Mouse Model May Open Autism Treatment Avenues

The hallmark of an excellent researcher is an open mind. That flexibility and openness is what led Nina Schor, the William H. Eilinger Chair of Pediatrics at the University of Rochester, to follow a h...

Unanswered questions about higher potency statins and the risk of new diabetes

Dormuth and colleagues conclude that the use of higher potency statins is associated with a moderate increase in new onset diabetes compared with lower potency drugs.1I have several comments on this.....

Cholesterol Drugs May Speed Healing After Surgery

THURSDAY, July 31, 2014 -- Recovery time after surgery may be reduced for patients taking the cholesterol-lowering medications known as statins, according to a new study. The study's Irish researchers...

Novartis apologizes for not disclosing side-effects of leukemia drugs sooner

TOKYO (Reuters) - The Japanese unit of Novartis AG apologized on Thursday for failing to report to authorities in a timely manner side-effects of its leukemia drugs, in the company's latest scandal in...

UPDATE 1-Novartis apologises for not disclosing side-effects of leukaemia drugs sooner

TOKYO, July 31 (Reuters) - The Japanese unit of Novartis AG apologised on Thursday for nfailing to report to authorities in a timely manner side-effects of its leukaemia drugs, in the company's latest...

Celgene: Constantly Adding Signature Drugs To Its Healthy Portfolio

By Balanced Investing:As we approach the end of July, many companies are busy filing their quarter end results. Some have reported positive earnings surprises while others may have just missed the con...

Consumer Reports Warns Against the Risks of Prescription and Over-The-Counter Painkillers

CR urges U.S. Food and Drug Administration to take stronger steps to reduce the dangers of pain-relief medications YONKERS, NY (PRWEB) July 31, 2014 Some pain relief medications can be as addictive a...

Anti-cholinergic drugs could be responsible for decline in cognitive, physical function in elderly patients

Drugs widely prescribed to the elderly could be responsible for a decline in cognitive and physical function according to research from the University of East Anglia and the Regenstrief Institute.

Mystic Pharmaceuticals Receives Notice of Allowance for Novel Powder Drug Delivery Technology

Unit of Use Powder Drug Packaging and Delivery Technology Enables Innovation of New Classes of Drug/Device Combination Products Mystic Pharmaceuticals, Inc., a privatel...

Events [0 Results]

None

Companies [220 Associated Companies listed on BioPortfolio]

Biosceptre

Biosceptre has identified a pan-cancer target, present in many cancer types, and importantly not found in healthy tissue. Early research and initial evidence suggest that drugs di...

Hydra Biosciences, Inc.

Hydra Biosciences is a privately-held biopharmaceutical company based in Cambridge, Massachusetts, and develops drugs to treat pain, inflammation, anxiety and other diseases using...

DesignMedix, Inc.

DesignMedix, Inc. was founded in 2008 to develop drugs to overcome drug resistance. The company’s initial focus is on oral drugs to treat malaria, which kills over 600,000 pe...

Ichor Medical Systems, Inc.

Ichor Medical Systems’ TriGrid™ Delivery System (TriGrid) is the first integrated and fully automated device for electroporation-mediated DNA administration in humans. I...

Sonrgy, Inc.

Sonrgy is a preclinical stage biotechnology company based in San Diego, California that is developing a targeted chemotherapy delivery platform to improve survival and quality of...

Zocere, Inc.

Headquartered in Albuquerque, New Mexico, Zocere, Inc., is a startup pharmaceutical company developing injectable, neuroprotectant drugs intended to combat stroke and other neurol...

Carmot Therapeutics

Carmot is pioneering a transformative drug discovery approach, Chemotype Evolution, to identify superior therapeutics for human diseases. Chemotype Evolution is a proprietary tech...

CancerCare Co-Payment Foundation

The CancerCare® Co-Payment Assistance Foundation (CCAF) is a nonprofit 501(c)(3) organization dedicated to helping people afford co-payments for chemotherapy and targeted treat...

Concert Pharmaceuticals Inc.

Concert Pharmaceuticals is a clinical stage biotechnology company with a broad development pipeline targeting renal disease, CNS disorders, inflammation and hematologic disorders....

Etubics Corporation

Etubics Corporation, based in Seattle, Wash., is a clinical stage bio-pharmaceutical company, which has developed a proprietary platform technology consisting of a next generation...

Clinical Trials [137 Associated Clinical Trials listed on BioPortfolio]

A Study on Possible Interactions Between Protease Inhibitors (Anti-HIV Drugs) and Drugs Which Lower the Level of Fat in Your Blood

The purpose of this study is to find out whether taking protease inhibitors (anti-HIV drugs) together with lipid-lowering drugs (drugs which lower the amount of fat in the blood) has an ef...

A Study to Evaluate the Effects of Anti-HIV Drugs in HIV-Positive Patients Who Also Have Hepatitis C Infection

This study evaluates patients infected with both HIV and Hepatitis C virus (HCV) who are receiving anti-HIV drugs. The purpose of this study is to learn more about HCV infection in patien...

A Study of Stavudine in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drugs

To make stavudine (d4T) available to patients with advanced HIV disease for whom no alternative antiretroviral is satisfactory. To study the safety and efficacy of two dose levels in a twi...

An Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of Dideoxycytidine (ddC) in Patients With AIDS or Advanced ARC Who Previously Demonstrated Intolerance to Zidovudine (AZT) in Protocol N3300 or N3492

To demonstrate that zalcitabine (dideoxycytidine; ddC) monotherapy is safe and tolerable in the treatment of patients with AIDS or advanced AIDS related complex (ARC) who previously demons...

A Study of Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

The purpose of this study is to see if it is safe and effective to give efavirenz plus stavudine plus lamivudine to patients who have never taken anti-HIV drugs.

A Study of Combivir Plus Abacavir Plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs

The purpose of this study is to test the effectiveness of Combivir plus abacavir plus 141W94 in patients who previously have used anti-HIV drugs.

The Safety and Effectiveness of MK-639 and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

To compare the effects on CD4 counts and safety of MK-639 (indinavir, IDV) and AZT administered concomitantly to MK-639 alone and AZT alone in HIV-1 seropositive patients.

The Safety and Effectiveness of Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs

To evaluate the safety and antiretroviral activity of saquinavir soft gelatin capsule formulation (SQV-SGC) in combination with other antiretroviral drugs.

A Study of MKC-442 in Combination With Other Anti-HIV Drugs

The purpose of this study is to see if it is safe and effective to give MKC-442 plus stavudine (d4T) plus didanosine (ddI) plus hydroxyurea.

A Study of Three Drug Combination Therapies in HIV-Infected Patients Who Have Never Been Treated With Anti-HIV Drugs

The purpose of this study is to see if it is safe and effective to give one of three different triple-drug combinations to HIV-infected patients who have never been treated with anti-HIV d...

Medical and Biotech [MESH] Definitions

Drugs used by veterinarians in the treatment of animal diseases. The veterinarian's pharmacological armamentarium is the counterpart of drugs treating human diseases, with dosage and administration adjusted to the size, weight, disease, and idiosyncrasies of the species. In the United States most drugs are subject to federal regulations with special reference to the safety of drugs and residues in edible animal products.

Drugs which have received FDA approval for human testing but have yet to be approved for commercial marketing. This includes drugs used for treatment while they still are undergoing clinical trials (Treatment IND). The main heading includes drugs under investigation in foreign countries.

The use of multiple drugs administered to the same patient, most commonly seen in elderly patients. It includes also the administration of excessive medication. Since in the United States most drugs are dispensed as single-agent formulations, polypharmacy, though using many drugs administered to the same patient, must be differentiated from DRUG COMBINATIONS, single preparations containing two or more drugs as a fixed dose, and from DRUG THERAPY, COMBINATION, two or more drugs administered separately for a combined effect. (From Segen, Dictionary of Modern Medicine, 1992)

Drugs that mimic the effects of parasympathetic nervous system activity. Included here are drugs that directly stimulate muscarinic receptors and drugs that potentiate cholinergic activity, usually by slowing the breakdown of acetylcholine (CHOLINESTERASE INHIBITORS). Drugs that stimulate both sympathetic and parasympathetic postganglionic neurons (GANGLIONIC STIMULANTS) are not included here.

Drugs used to specifically facilitate learning or memory, particularly to prevent the cognitive deficits associated with dementias. These drugs act by a variety of mechanisms. While no potent nootropic drugs have yet been accepted for general use, several are being actively investigated.

Search BioPortfolio:
Advertisement
Advertisement
review and buy Diseasemodifying drugs market research data and corporate reports here

Channels Quicklinks